Our Services
Medical Information
Helpful Resources
Published on: 4/4/2026
Jardiance is generally avoided in pregnancy and monitored closely due to limited human safety data, potential effects on fetal kidney development especially in the second and third trimesters, and added risks like dehydration, low blood pressure, and rare euglycemic ketoacidosis.
Safer options such as insulin and sometimes metformin are usually preferred, and if you become pregnant while taking Jardiance contact your clinician before making changes; see the detailed guidance below on warning signs, monitoring, and individualized decision factors that could influence your next steps.
Managing diabetes during pregnancy is essential for the health of both mother and baby. Blood sugar levels that are too high can increase the risk of complications, including preeclampsia, premature birth, and excessive birth weight. Because of these risks, medication choices during pregnancy are carefully evaluated.
One medication that often raises questions is Jardiance (empagliflozin). While it is widely used to treat type 2 diabetes in non-pregnant adults, it is closely monitored and generally not recommended during pregnancy. Understanding why can help you make informed decisions with your healthcare provider.
Jardiance belongs to a class of medications called SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors). It works by:
In non-pregnant adults, Jardiance can be highly effective. However, pregnancy changes how medications affect the body — and the developing baby.
There are no well-controlled clinical trials of Jardiance in pregnant women. Because of this, healthcare providers rely on animal studies and post-marketing data.
In animal studies, SGLT2 inhibitors have shown potential risks to developing kidneys when exposure occurred during certain stages of pregnancy. Since a baby's kidneys continue developing in the second and third trimesters, medications that affect kidney function are approached cautiously.
When safety data is limited, doctors typically recommend medications with a longer, proven safety history in pregnancy — such as insulin.
Jardiance works directly on the kidneys. During pregnancy:
Although human data is limited, this theoretical risk is significant enough that most professional guidelines recommend avoiding SGLT2 inhibitors during pregnancy, especially in the second and third trimesters.
One of the known Jardiance side effects is increased urination. While this helps lower blood sugar, it can also:
Pregnant women already experience changes in blood volume and circulation. Additional fluid loss may increase the risk of complications, especially if nausea or vomiting is present.
Although uncommon, SGLT2 inhibitors like Jardiance have been associated with euglycemic diabetic ketoacidosis (DKA) — a serious condition where acid levels rise in the blood even when blood sugar is not extremely high.
Pregnancy itself increases the risk of DKA. Combining pregnancy with a medication that may elevate that risk makes doctors cautious.
Symptoms of DKA may include:
DKA is a medical emergency and requires immediate treatment.
Understanding general Jardiance side effects helps explain why the medication requires close monitoring, even outside of pregnancy.
Common side effects include:
More serious but less common side effects include:
Pregnancy can increase susceptibility to infections and dehydration, which is another reason providers typically choose alternatives.
For women with:
Insulin is the gold standard treatment during pregnancy because:
Depending on severity, treatment may include:
Your provider will individualize treatment based on:
Uncontrolled diabetes during pregnancy can increase the risk of:
The goal is steady, well-controlled glucose levels — not just lowering numbers quickly, but maintaining stability safely.
If you are currently taking Jardiance and discover you are pregnant:
Your doctor will evaluate:
Often, the medication will be discontinued and replaced with insulin or another safer option.
In rare situations, medication decisions may be complex. If a patient has significant cardiovascular disease or other serious conditions, specialists may weigh risks and benefits carefully.
Management may involve:
Close monitoring may include:
The goal is always to protect both mother and baby.
If you are unsure whether you may have diabetes — or if you are experiencing symptoms such as:
You can use a free AI-powered Diabetes Mellitus symptom checker to help understand what your symptoms might mean and prepare for a more informed conversation with your healthcare provider.
However, an online tool should never replace professional medical care.
Jardiance is an effective medication for many adults with type 2 diabetes. It has proven cardiovascular and kidney benefits in appropriate patients.
But pregnancy changes the equation.
Because of:
Most medical guidelines recommend avoiding Jardiance during pregnancy, especially after the first trimester.
This cautious approach is not meant to alarm — it reflects a commitment to safety when evidence is limited.
Seek urgent medical attention if you experience:
These symptoms could signal serious complications.
Jardiance is a valuable medication for many adults with type 2 diabetes, but it is closely monitored and generally avoided during pregnancy due to limited safety data and potential risks to fetal kidney development.
If you are pregnant or planning to become pregnant:
Most importantly, speak to a doctor promptly about any symptoms that feel severe, unusual, or potentially life-threatening. Diabetes in pregnancy is manageable with the right care plan — and early, proactive treatment makes a significant difference.
With careful monitoring and medical guidance, most women with diabetes go on to have healthy pregnancies and healthy babies.
(References)
* Chen L, Luo N, Liu M, et al. Safety of Sodium-Glucose Cotransporter 2 Inhibitors during Pregnancy: A Systematic Review. J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1470-e1480. doi: 10.1210/clinem/dgab866. PMID: 34870349.
* American Diabetes Association. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S273-S289. doi: 10.2337/dc24-S015. PMID: 38198539.
* Vrachnis N, Papapanagiotou A, Bakas P, et al. Sodium-glucose co-transporter 2 inhibitors in pregnancy: a systematic review. J Matern Fetal Neonatal Med. 2024 Dec;37(1):2343202. doi: 10.1080/14767058.2024.2343202. PMID: 38662369.
* Balsalobre-Li M, Lattouf R, Rueda-Ruzafa L, et al. SGLT2 Inhibitors during pregnancy: an updated review for clinicians. Int J Mol Sci. 2023 Jan 26;24(3):2381. doi: 10.3390/ijms24032381. PMID: 36768800; PMCID: PMC9916124.
* Efeoglu T, Aksoy N. Current and Emerging Pharmacotherapeutic Strategies for Gestational Diabetes Mellitus and Type 2 Diabetes in Pregnancy. Adv Exp Med Biol. 2024;1465:109-122. doi: 10.1007/978-3-031-48227-2_8. PMID: 38334460.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.